US protection ending in 2026: Bones, joints and muscles
As of the edition of 20 October 2026, 9 drugs have US protection that ends (or has ended) in 2026 in bones, joints and muscles; 3 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
9 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Dasatinib anhydrous | Ended 2026 (exclusivity) | Marketed | ABL1, BLK, FGR | 12 | |
| Deflazacort | Ended 2026 (exclusivity) | Marketed | PTC Therapeutics | NR3C1 | 0 |
| Elvitegravir | Ends 2026 (patent) | Marketed | Gilead Sciences | 0 | |
| Escitalopram | Ended 2026 (exclusivity) | Marketed | AbbVie | SLC6A4 | 4 |
| Golodirsen | Ends 2026 (exclusivity) | Marketed | Avi Biopharma | DMD | 0 |
| Lacosamide | Ended 2026 (exclusivity) | Marketed | UCB | SCN10A, SCN11A, SCN1A | 0 |
| Onabotulinumtoxina | Ended 2026 (orphan exclusivity) | Marketed | AbbVie | SNAP25 | 0 |
| Pasireotide | Ends 2026 (patent) | Marketed | Recordati Rare Diseases | SSTR2, SSTR3, SSTR5 | 0 |
| Sitagliptin | Ends 2026 (patent) | Marketed | Merck & Co. | DPP4 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2026 in bones, joints and muscles
In the product3 of these 9 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.